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Nebivolol and metoprolol are β1-adrenergic receptor blockers with different properties. We hypothesized
that nebivolol, but not metoprolol, could attenuate prooxidant and proﬁbrotic mechanisms of hyperten-
sion and therefore protect against the vascular remodeling associated with hypertension. Hypertension
was induced in male Wistar rats by clipping the left renal artery. Six weeks after surgery, hypertensive
and sham rats were treated with nebivolol (10 mg kg−1 day−1) or metoprolol (20 mg kg−1 day−1) for
4 weeks. Systolic blood pressure was monitored weekly. Morphologic changes in the aortic wall were
studied in hematoxylin/eosin and picrosirius red sections. Aortic NAD(P)H activity and superoxide
production were evaluated by luminescence and dihydroethidium, respectively, and TBARS levels were
measured in plasma. Aortic nitrotyrosine staining was evaluated to assess peroxynitrite formation. TGF-β
levels and p-ERK 1/2 expression were determined by immunoﬂuorescence and Western blotting,
respectively. Matrix metalloproteinase (MMP) activity and expression were determined by in situ
zymography, gel zymography, Western blotting, and immunoﬂuorescence, and TIMP-1 was assessed
by immunohistochemistry. Both β1-receptor antagonists exerted very similar antihypertensive effects.
However, while metoprolol had no signiﬁcant effects, nebivolol signiﬁcantly attenuated vascular
remodeling and collagen deposition associated with hypertension. Moreover, nebivolol, but not
metoprolol, attenuated hypertension-induced increases in aortic NAD(P)H oxidase activity, superoxide
production, TBARS concentrations, nitrotyrosine levels, TGF-β upregulation, and MMP-2 and -9 expres-
sion/activity. No effects on p-ERK 1/2 and TIMP-1 expression were found. These results show for the ﬁrst
time that nebivolol, but not metoprolol, attenuates prooxidant and proﬁbrotic mechanisms involving
TGF-β and MMP-2 and MMP-9, which promote vascular remodeling in hypertension.
& 2013 Elsevier Inc. All rights reserved.Introduction
Hypertension promotes vascular remodeling associated with
exposure of the vascular wall to chronic increases in blood pressure
[1,2]. Indeed, sustained increases in blood pressure lead to collagen
and elastin fragmentation and disrupt extracellular matrix (ECM)
organization of conductance vessels. This process involves multiple
mechanisms, leading to vascular cell proliferation, migration, andll rights reserved.
llular matrix; ERK 1/2, extra-
; MMP, matrix metallopro-
ng grown factor; TBARS,
@yahoo.comabnormal ECM synthesis and deposition [1–3]. In this respect,
growing evidence implicates imbalanced matrix metalloproteinase
(MMP) activity in experimental hypertension-induced vascular
remodeling, especially MMP-2 [4–9]. Supporting these animal
studies, clinical ﬁndings also implicate abnormal MMP activity in
hypertension [10–12]. Adding complexity, a new intracellular iso-
form of MMP-2 has been recently described, and it is involved in
cardiovascular disorders [13].
MMPs are critically regulated at posttranslational levels by
proteolytic cleavage by other MMPs or oxidative and/or nitrosative
stress [14,15]. Drugs with antioxidant properties attenuate
hypertension-induced vascular remodeling, possibly as a result of
less MMP activation [7,16–18]. However, antioxidants can also
decrease hypertension-induced vascular remodeling by attenuat-
ing MMP-induced activation of proﬁbrotic factors clearly involved
in this process, including transforming grown factor (TGF)-β
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induced activation of extracellular regulated kinase 1/2 (ERK 1/2)
[21], which is another proﬁbrotic factor contributing to vascular
remodeling of hypertension [2]. While lowering blood pressure
clearly has a major impact on hypertension-induced vascular
alterations, antihypertensive drugs with antioxidant properties
may offer protection against the vascular alterations caused by
hypertension that adds to their effects of blood pressure.
In this study, we compared the effects of two β1-adrenergic
receptor blockers (nebivolol and metoprolol) on the vascular
alterations caused by 2 kidney, one clip (2K1C) hypertension.
Our group has consistently shown increased oxidative stress and
MMP activity in this animal model of hypertension, and inhibition
of these alterations fully prevented vascular remodeling, even
though blood pressure remained increased [5,16,22]. Our previous
studies suggest that oxidative stress and imbalanced MMP activity
play an important role in the vascular alterations of hypertension,
independently of blood pressure [5,16,22]. Therefore, because
nebivolol, but not metoprolol, has antioxidant properties [23–26],
we hypothesized that nebivolol, but not metoprolol, could decrease
NAD(P)H oxidase activation in the vasculature from 2K1C hyper-
tensive rats and attenuate MMP activation, and proﬁbrotic altera-
tions associated with vascular remodeling. Our ﬁndings may offer a
mechanistic insight to clinical [27] and experimental [28] studies
showing reduced arterial stiffness in association with nebivolol, but
not metoprolol.Materials and methods
Animals and treatments
The study complied with guidelines of the Faculty of Medicine
of Ribeirao Preto, University of Sao Paulo, and the animals were
handled according to the guiding principles published by the
National Institutes of Health. Male Wistar rats (180–200 g)
obtained from the colony at University of São Paulo were main-
tained on 12-h light/dark cycle at 25 1C with free access to rat
chow and water. 2K1C hypertension was induced as previously
described [29]. A silver clip (0.2 mm) was placed in the left
renal artery of rats under anesthesia with ketamine 100 mg/kg
and xylazine 10 mg/kg ip. Sham-operated rats underwent
the same surgical procedure except for the clip placement. Tail
systolic blood pressure (SBP) was assessed weekly by tail-cuff
plethysmography.
Treatments were started 6 weeks after surgery and maintained
for 4 weeks. The animals were randomly assigned to one of
6 groups: 2K1C or sham animals that received vehicle (ethanol
2% v/v), 2K1C and sham animals that received metoprolol (Meto)
20 mg kg−1 day−1 (Selozok; AstraZeneca), and 2K1C and sham
animals that received nebivolol (Nebi) 10 mg kg−1 day−1 (Nebilet
Biolab). The drugs were given by gavage, and the doses were
chosen on the basis of previous studies using the same doses of
both β-blockers, which produced similar effects [26,30]. At the end
of the experimental period, animals were anesthetized as
described above and killed by decapitation. Arterial blood samples
were centrifuged at 1000g for 10 min and plasma fractions were
immediately stored at −70 1C until used for biochemical measure-
ments. Their thoracic aorta was removed and stored at −70 1C.
Morphometric analysis and composition of the vascular wall
Thoracic aortas were harvested, cleaned of connective tissue,
ﬁxed in 4% phosphate-buffered paraformaldehyde (Carlo Erba
Reagents), pH 7.4, and embedded in parafﬁn blocks. Four-
micrometer-thick slices were stained with hematoxylin (Fluka)and eosin (Fluka) (H&E) and picrosirius red (stain kit). Aortic
media cross-sectional area (CSA) was calculated by subtracting the
lumen internal area (Ai) from the external area (Ae) measured in
tissue sections (50 ) [5]. The external and internal diameters (ED
and ID, respectively) were calculated as the square root of 4Ae/π
(ED) and 4Ai/π (ID), respectively, and media thickness (M) was
calculated as (ED–ID)/2. Finally, M to lumen diameter (M/L) was
also calculated. The number of vascular smooth muscle cells
(VSMCs) in the aortic media layer was measured by the tridimen-
sional dissector method, which is independent of orientation,
form, and size of the nucleus [5,22]. Picrosirius red staining was
used to determine the collagen content in the aortic media layer
with light microscopy (DMLB; Leica, Bensheim, Germany) and the
image was captured at 400. These structural analyses in the
media were evaluated by using ImageJ Program (NIH–National
Institutes of Health) as previously described [5,22].
Assessment of vascular ROS formation
NAD(P)H-dependent superoxide production was measured in
aortic rings from rats. Aortic rings were transferred to lumines-
cence vials containing 1 ml of Hanks buffer (Sigma), pH 7.4. After
equilibration and background count, lucigenin (5 mmol L−1; Sigma,
M8010) and NAD(P)H (300 mmol L−1; Sigma) were added to the
vials and the luminescence count was measured continuously for
15 min in a Berthold FB12 single tube luminometer at 37 1C.
Background signals from aortic rings were subtracted from the
NAD(P)H-driven signals and the results were normalized by aortic
dry weight and reported as relative luminescence units (RLU)
mg−1 min−1, as previously described [31].
Dihydroethidium (DHE; Sigma) was used to evaluate in situ
production of ROS. Brieﬂy, aortic tissues were vertically embedded
in Tissue-tek. Aortic sections (5-μm-thick slices) were incubated
with DHE 10 mmol L−1 (diluted in DMSO 0.01%; Sigma) for 30 min,
and then washed 3 times with cold PBS (Sigma), pH 7.4, as
previously described [31]. Sections were examined by ﬂuorescence
microscopy (Leica Imaging Systems Ltd., Cambridge, England) and
the image was captured at 400. Red ﬂuorescence was measured
using the ImageJ Program (National Institutes of Health). Red
ﬂuorescence intensity from 20 ﬁelds (corresponding to 20–30%
of the total aortic area) selected around the vessel circumference
was measured, and the arithmetic mean of the ﬂuorescence from
these ﬁelds was calculated for each slide.
Plasma lipid peroxide levels were determined by measuring
thiobarbituric acid-reactive substances (TBARS) using a ﬂuori-
metric method that requires excitation at 515 nm and emission
at 553 nm as previously described [32]. The lipoperoxide levels
were expressed in terms of malondialdehyde (MDA) (nmol ml−1).
Immunohistochemistry to assess nitrotyrosine and TIMP-1 expression
In order to assess nitrotyrosine and TIMP-1 (an endogenous
tissue inhibitor of MMP) levels and location in the thoracic aorta,
frozen aortic 5-mm sections were ﬁxed in acetone and incubated
with 3% H2O2 in water for 10 min at room temperature to block
tissue peroxidase activity. Then tissue sections were incubated for
1 h with a speciﬁc rabbit anti-nitrotyrosine antibody (Millipore,
USA) or mouse anti-TIMP-1 antibody (MAB3300, Chemicon) in
dark humidiﬁed chambers. After washing 3 times, an anti-rabbit
HRP-conjugated secondary antibody was added to the sections for
1 h at room temperature, and then washed 3 times with cold PBS.
Positive staining appeared as a dark brown color visualized
by adding 3,3′-diaminobenzidine tetrahydrochloride (DAB) chro-
mogen buffer for 20 min and washed 3 times with cold PBS
(all solutions were from anti-rabbit poly horseradish peroxidase
immunohistochemistry detection kit, Chemicon, USA, DAB-150).
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optic microscopy (Leica Imaging Systems Ltd., Cambridge, Eng-
land) and the image was captured at 400. The amount of
nitrotyrosine in stained sections was obtained by quantiﬁcation
of the immunoreactivity shown as brown color intensity of 20
ﬁelds selected around the vessel circumference, which correspond
to approximately 20–30% of the total aortic area (interassay
coefﬁcient of variation less than 4%). The ImageJ Program (National
Institutes of Health) was used to quantify nitrotyrosine, as pre-
viously described [33].
Immunoﬂuorescence to assess TGF-β and MMP-9 levels
Frozen 5-mm aortic sections were incubated with antibody
against TGF-β (polyclonal mouse anti-TGF-β 1/2/3; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA) or against MMP-9
(monoclonal mouse anti-MMP-9, MAB3309, Chemicon) in dark
humidiﬁed chambers for 1 h and washed 3 times with cold PBS.
Then anti-mouse rhodamine conjugated secondary antibody
(1:200 dilution, Chemicon) was added for 1 h and washed 3 times
with cold PBS. Sections were examined by ﬂuorescent microscopy
(Leica Imaging Systems Ltd., Cambridge, England) and the images
were captured at 400. Red ﬂuorescence intensity was evaluated
by using ImageJ Program (National Institutes of Health) in 20 ﬁelds
selected around the vessel circumference (interassay coefﬁcient of
variation less than 3%), and the arithmetic of 20 ﬁelds was
calculated for each slide.
Measurements of aortic MMP-2 levels by gelatin zymography
and gelatinolytic activity by in situ zymography
Gelatin zymography was performed as previously described
[29]. Tissue extracts (30 mg of protein) were subjected to electro-
phoresis on 12% SDS-PAGE copolymerized with gelatin (1%;
Himedia). The gel was incubated for 1 h at room temperature in
a 2% Triton X-100 (Synth) solution after electrophoresis was
complete. Then it was incubated at 37 1C for 18 h in Tris-HCl
buffer (Tris 50 mmol L−1, ZnCl2 1 μmol L−1, both from Sigma), pH
7.4, and 10 mmol L−1 CaCl2. Then gels were stained with 0.05%
Coomassie brilliant blue G-250 (Sigma) and destained with 30%
methanol and 10% acetic acid. Gelatinolytic activity was detected
as an unstained band against the background of gelatin stained by
Coomassie blue. Band densitometry was quantiﬁed by a Kodak
Electrophoresis Documentation and Analysis System (EDAS) 290
(Kodak, Rochester, NY).
Gelatinolytic activity in media layer from frozen thoracic aorta
was measured using DQ gelatin (Molecular Probes, OR, USA) as
previously described [16,22]. Aortic tissues were vertically frozen
in Tissue-tek and cut in 5-mm sections, which were incubated with
1.0 μg ml−1 DQ gelatin in Tris-CaCl2 buffer (Tris 50 mmol L−1, CaCl2
10 mmol L−1, ZnCl2 1 μmol L−1, all from Sigma) in dark humidiﬁed
chambers for 1 h, and washed 3 times with cold PBS (Sigma).
The sections were examined by ﬂuorescent microscopy (Leica
Imaging Systems Ltd., Cambridge, England) and the images were
captured at 400. Proteolytic activity was observed as bright
green ﬂuorescence, which was evaluated by using ImageJ Program
(National Institutes of Health) in 20 ﬁelds selected around the
vessel circumference (interassay coefﬁcient of variation less than
3%), and the arithmetic mean of 20 ﬁelds was calculated for each
slide. To conﬁrm MMP activity in the sections, we used phenan-
throline (Sigma) at 50 mmol L−1, which fully inhibited gelatinolytic
activity in the aorta (data not shown).
Aortic gelatinolytic activity was colocalized with aortic MMP-2
expression by immunoﬂuorescence. After incubation with DQ
gelatin, tissue sections were ﬁxed in 4% phosphate-buffered
paraformaldehyde (Carlo Erba Reagents), pH 7.4, and incubatedfor 1 h with mouse anti-MMP-2 (1:500 dilution; Chemicon), and
then washed 3 times with cold PBS. Then a rhodamine-conjugated
secondary antibody (1:200 dilution; Chemicon) was added for 1 h
and washed 3 times with cold PBS. The sections were examined by
ﬂuorescent microscopy (Leica Imaging Systems Ltd., Cambridge,
England) and the images were captured at 400. Red ﬂuores-
cence intensity was evaluated by using ImageJ Program (NIH) as
described above, and the Picasa 3 program was used to colocalize
the aortic microphotographs.
Western blotting assessment of aortic MMP-2 and p-ERK 1/2 levels
Aortas from 2K1C and sham rats were homogenized on ice-cold
RIPA buffer (Sigma, R0278). Protein extracts (40 μg) were subject
to SDS-PAGE using a 7% (MMP-2) or 12% (p-ERK 1/2) polyacryla-
mide gel after boiling for 5 min under reducing conditions. To
conﬁrm the molecular mass of the proteins, molecular weight
standards (Thermo Scientiﬁc) were loaded into the gels. Proteins
were transferred to nitrocellulose membranes and blocked with
TBST (NaCl 100 mmol L−1; Tris-Cl 100 mmol L−1; Tween 0.1%) and
5% bovine serum albumin. The membranes were incubated over-
night at 4 1C with mouse anti-MMP-2 (1:500 dilution; Chemicon,
MAB3308) or rabbit anti-phosphorylated-ERK 1/2 (anti-p-ERK 1/2
1:1000 dilution; Millipore) antibodies, and mouse anti-β-actin
(1:5000 dilution; Millipore MAB1501), which was used as a
loading control [34]. Blots were then rinsed in TBST 3 times for
15 min. Then the appropriate horseradish peroxidase (HRP)-sec-
ondary goat anti-mouse antibody (1:1000 dilution; Millipore),
HRP-secondary goat anti-rabbit antibody (1:1000 dilution; Milli-
pore), and chemiluminescence ECL (Millipore) were used. Immu-
nolabeled proteins were detected by ImageQuant 350 detection
system (GE Healthcare) and the signal intensities were quantiﬁed
using ImageJ Program (National Institutes of Health).
In vitro effects of metoprolol and nebivolol on MMP-2 activity
To examine whether metoprolol or nebivolol directly inhibits
MMP-2 activity in vitro, we studied the direct effects of both drugs
on recombinant human MMP-2 activity (rhMMP-2) obtained as
previously described [35]. Proteolytic activity of rhMMP-2
(300 ng) was measured using DQ gelatin (Molecular Probes, OR,
USA) at 5 μg ml−1 in Tris-CaCl2 buffer (Tris 50 mmol L−1, CaCl2
10 mmol L−1, ZnCl2 1 mmol L−1) after incubation with vehicle
(DMSO 0.01% v/v) or nebivolol (Nebi – 0, 1, 10, and 100 mmol L−1;
Sigma) or metoprolol (Meto – 0, 1, 10, and 100 mmol L−1; Sigma) at
37 1C for 2 h. A standard curve of gelatinolytic activity was
prepared as recommended by the manufacturer. This ﬂuorimetric
method requires excitation at 495 nm and emission at 515 nm.
Phenanthroline (Phen – 50 mmol L−1) was used as a positive control
for MMP-2 activity inhibition.
Statistical analysis
Results are expressed as means7SEM. Comparisons between
hypertensive groups were made with two- or one-way analysis of
variance (ANOVA) followed by the Tukey test. A probability value
o0.05 was considered signiﬁcant.Results
Nebivolol and metoprolol exerted similar antihypertensive effects
Baseline SBP was similar in the six experimental groups
(P40.05; Fig. 1A). As expected, SBP increased in the 2K1C+vehicle
group after the ﬁrst week (Po0.05; Fig. 1A), and no signiﬁcant
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0
Fig. 1. Effects of treatments on systolic blood pressure (SBP) and structural alterations induced in the aortas by 2K1C hypertension. Panel A shows systolic SBP measured by
tail-cuff method along the study (n¼10–12 per group). Panel B shows representative photographs of aortic samples (400) stained by hematoxylin and eosin. Panels C, D,
and E show the values for vascular smooth muscle cell numbers per length of aorta, media to lumen ratio (M/L), and thoracic aorta medial cross-sectional area (CSA),
respectively (n¼6–8 per group). Values are expressed as mean+SEM. *Po0.05 for 2K1C+vehicle group versus sham groups; **Po0.05 for 2K1C+treatment group versus
2K1C+vehicle group.
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Nebivolol (Nebi) and metoprolol (Meto) treatments exerted similar
antihypertensive effects (SBP: 20677, 15179, and 1567
15 mm Hg in 2K1C+vehicle, 2K1C+Meto, and 2K1C+Nebi groups,
respectively; both Po0.05; Fig. 1A). Importantly, no signiﬁcant
differences in SBP were found when the 2K1C+Meto and the 2K1C
+Nebi groups were compared (P40.05; Fig. 1A).
Nebivolol, but not metoprolol, treatment decreased aortic remodeling
in 2K1C hypertension
Goldblatt hypertension was associated with arterial wall hyper-
trophy and signiﬁcant increases in number of cells (Figs. 1B and C)
in aortic media layer, increased aortic M/L ratio (Fig. 1D), and
increased CSA (Fig. 1E) when compared with the Sham+vehicle
group (all Po0.05). While nebivolol treatment decreased these
morphological alterations in hypertensive rats (28% decrease in
cell number, 18% decrease in M/L, and 24% decrease in CSA; all
Po0.05; Figs. 1C–E, respectively), metoprolol exerted no signiﬁ-
cant effects.
In line with these results, 2K1C hypertension increased col-
lagen surface in the aortic media layer, and nebivolol, but not
metoprolol, treatment prevented this alteration in hypertensive
rats (Po0.05; Figs. 2A and B).
Nebivolol treatment decreased aortic TGF-β, but not p-ERK 1/2
expression, in 2K1C hypertension
Higher TGF-β levels were found in the aortic media layer from
hypertensive rats compared with the Sham+vehicle group
(Po0.05; Figs. 2C and D), and treatment with nebivolol, but not
metoprolol, signiﬁcantly decreased this alteration (Po0.05;
Figs. 2C and D).
In parallel with TGF-β, 2K1C hypertension increased p-ERK 1/2
expression by approximately 100% (Po0.05; Fig. 2E and F).However, neither nebivolol nor metoprolol treatments attenuated
this alteration (P40.05; Figs. 2E and F).
Nebivolol, but not metoprolol, treatment decreased aortic NAD(P)H
oxidase activity, vascular ROS levels, nitrotyrosine levels, and plasma
lipid peroxide levels in hypertensive animals
Hypertension increased ROS levels in the aortic media layer
from rats in the 2K1C+vehicle group (Po0.05; Figs. 3A and B), and
this alteration was associated with increased aortic NAD(P)H
oxidase activity (Fig. 3C), and higher plasma MDA levels (Fig. 3D)
in these animals as compared to the Sham+vehicle group
(all Po0.05). While treatment with nebivolol blunted these
alterations reﬂecting increased oxidative stress by approximately
50% (all Po0.05; Figs. 3A–D), treatment with metoprolol exerted
no signiﬁcant effects.
In line with these results, hypertension increased aortic media
layer nitrotyrosine levels (Po0.05; Figs. 3E and F). However, while
treatment with nebivolol attenuated this alteration reﬂecting nitro-
sative stress (Po0.05; Figs. 3E and F), treatment with metoprolol
had no effects.
Nebivolol, but not metoprolol, treatment decreased aortic media layer
MMP-2 and MMP-9 expression and activity in hypertensive animals,
without affecting TIMP-1 levels
A representative zymogram of aortic extracts is shown in
Fig. 4A. This ﬁgure shows different bands corresponding to
different molecular weight MMP-2 forms (75, 72, and 64 kDa).
Aortas from 2K1C+vehicle rats showed higher levels all MMP-2
forms (Figs. 4B–D, respectively), thus resulting in higher total
MMP-2 levels (Po0.05; Fig. 4E) compared with the Sham+vehicle
group. Nebivolol, but not metoprolol, treatment attenuated 2K1C
hypertension-induced increases in 64 kDa MMP-2 (Po0.05;
Fig. 4D) and total MMP-2 levels (Po0.05; Fig. 4E).
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Fig. 2. Collagen surface in the media layer of aortas, TGF-β levels, and ERK1/2 expression in 2K1C hypertension and effects of treatments. Panel A shows representative
photographs of aortic samples (400) stained by picrosirius red. Panel B shows the values for surface area of collagen in the aortic media (n¼6–8 per group). Panel C shows
representative photographs of immunoﬂuorescence of TGF-β performed in the aortic media layer of rats (400). Panel D shows the quantiﬁcation of red staining of TGF-β
(n¼6–8 per group). Panel E shows p-ERK-1/2 expression in the thoracic aorta. Panel F shows densitometric intensity corresponding to p-ERK-1/2 normalized using β-actin in
each experimental group (n¼6–8 per group). *Po0.05 for 2K1C+vehicle group versus sham groups; **Po0.05 for 2K1C+Nebi group versus 2K1C+vehicle group.
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detected by Western blotting in the 2K1C+vehicle group com-
pared to the Sham+vehicle group (Po0.05; Figs. 4F and G), and
nebivolol, but not metoprolol, treatment blunted this alteration
associated with 2K1C hypertension (Po0.05; Figs. 4F and G).
Giving further support to zymogram results, in situ gelatinolytic
activity was measured and approximately 60% greater green
ﬂuorescence was found in the media layer of thoracic aorta in
the 2K1C+vehicle group compared to the Sham+vehicle group
(Po0.05; Figs. 5A and B). Again, nebivolol, but not metoprolol,
treatment reduced 2K1C hypertension-induced increases in gela-
tinolytic activity (Po0.05; Figs. 5A and B).
In parallel with the in situ gelatinolytic MMP activity, the red
ﬂuorescence showing MMP-2 immunolocalization was approxi-
mately 60% greater in the 2K1C+vehicle group compared to the
Sham+vehicle group (Po0.05; Figs. 5A and C). Again, nebivolol,
but not metoprolol, treatment blunted this alteration associated
with hypertension (Po0.05; Figs. 5A and C).
In line with MMP-2 results, the red ﬂuorescence showing
MMP-9 immunolocalization was approximately 30% greater in
the 2K1C+vehicle group compared to the Sham+vehicle group
(Po0.05; Figs. 6A and B). Again, nebivolol, but not metoprolol,
treatment blunted this alteration associated with hypertension
(Po0.05; Figs. 6A and B).TIMP-1 levels were analyzed by immunohistochemistry showed
no signiﬁcant differences between groups (P40.05; Figs. 6A and C).
Neither nebivolol, nor metoprolol, affect in vitro MMP-2 activity
Since nebivolol or metoprolol treatments could inhibit MMP-2
activity, we studied the direct effects of both drugs on enzyme
activity. Fig. 6D shows that neither nebivolol nor metoprolol
exerted signiﬁcant effects on hrMMP-2 activity, even when these
drugs were studied at very high concentrations (P40.05; Fig. 6D).
However, phenanthroline, which was used as positive control to
inhibit MMP-2 activity, blunted MMP-2 activity (Po0.01).Discussion
This is the ﬁrst study to show that antioxidant effects of
nebivolol treatment are associated with blunted vascular MMP-2
and MMP-9 up-regulation, decreased aortic TGF-β expression, and
prevention against vascular proﬁbrotic alterations and remodeling
associated with hypertension. In contrast, these protective effects
were not found with metoprolol treatment, although both
β1-blockers exerted very similar antihypertensive effects. Our obser-
vations provide novel mechanistic insights about the beneﬁcial
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Fig. 3. Effects of treatments on vascular ROS production, NADPH oxidase activity, plasma lipid peroxide concentrations, and nitrotyrosine levels in 2K1C hypertension. Panel
A shows representative photomicrographs (400) with red ﬂuorescence of dihydroethidium (DHE)-aortic cryosections. Panel B shows the quantiﬁcation of aortic red
ﬂuorescence in each experimental group (n¼6–8 per group). Panel C shows nonphagocytic, reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent
superoxide production measured as lucigenin chemiluminescence in the aortic rings (n¼8–10 per group). Panel D shows thiobarbituric acid-reactive substances
concentrations in plasma samples expressed in terms of malondialdehyde (MDA; n¼10 per group). Panel E shows representative photographs of immunostaining of
nitrotyrosine performed in the aortic media layer of rats (400). Panel F shows the quantiﬁcation of brown staining of nitrotyrosine (n¼6–8 per group). *Po0.05 for 2K1C
+vehicle group versus sham groups; **Po0.05 for 2K1C+Nebi group versus 2K1C+vehicle group.
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β1 adrenoceptor-blocking properties or blood pressure reduction.
This suggestion is based on most of our results showing that
metoprolol did not signiﬁcantly attenuate the alterations associated
with hypertension, whereas nebivolol did. However, it is important
to note that atenolol tended to attenuate some of these alterations, as
shown in Figs. 2 and 3.
Treatment with both β1-blockers resulted in similar reductions
in blood pressure, and this important observation is in agreement
with previous ﬁndings showing that the doses of β1-blockers used
in the present study resulted in similar antihypertensive effects
[30] or similar decreases in heart rate [26]. Therefore, it is
reasonable to believe that the differences between β1-blockers
reported here are probably not due to differences in antihyper-
tensive effects related to β1-adrenergic receptor blockade. Indeed,
our results showing that nebivolol, but not metoprolol, blunted
hypertension-induced vascular remodeling are consistent with
clinical ﬁndings showing that nebivolol, but not metoprolol, exerts
antioxidant effects and reduces arterial stiffness [27,28,36].
Hypertension induces several structural changes in the arterial
wall, with increased extracellular matrix synthesis and degrada-
tion, vascular cell proliferation, and migration. This remodeling
process involves the activation of several intracellular signaling
pathways by growth factors such angiotensin II and TGF-β [2,20].
Consistent with previous studies [5,29,34,37], we found that
hypertensive animals showed aortic hypertrophy, increasedvascular collagen content, and oxidative and nitrosative stress in
association with increased vascular MMP-2 and MMP-9 levels and
activity, and increased vascular levels of proﬁbrotic factors TGF-β
and p-ERK 1/2. These alterations may result from the activation of
the renin-angiotensin-aldosterone system, which is a major player
in this animal model of hypertension [34]. In fact, the angiotensin
II antagonist losartan prevented these alterations in 2K1C hyper-
tensive rats [34], thus suggesting a major role for angiotensin II.
Interestingly, angiotensin II acutely increased vascular ROS levels
and MMP activity [29], thus showing a direct link between
oxidative stress and MMP activity [14,15]. Increased oxidative
and nitrosative stress reported in the present study may have
activated ERK 1/2[21] and MMPs, which, in turn, activate TGF-β
[19,20] and promote collagen production and deposition [38].
While simply lowering blood pressure can attenuate this series
of complex proﬁbrotic mechanisms, antihypertensive drugs with
antioxidant effects are probably more efﬁcient in preventing them.
Nebivolol was previously shown to present intrinsic, direct,
superoxide scavenging properties [23,39]. This drug decreased
NADPH oxidase activity by down-regulating the expression of
the enzyme subunits (Rac1, p47 phox, and p67 phox subunits) in
a rat model of angiotensin II-induced hypertension and in a
transgenic rat model of renin-angiotensin-aldosterone system
activation [25,40,41]. In line with these works, we found that
2K1C hypertensive rats treated with nebivolol, but not with
metoprolol, had lower vascular NAD(P)H oxidase activity and
MMP-2
72kDa
β-actin
43 kDa
Fig. 4. MMP-2 expression in 2K1C hypertension and effects of treatments. Panel A shows a representative SDS-PAGE gelatin zymogram of aortic extracts. Molecular weights
of MMP-2 bands (75, 72, and 64 kDa MMP-2) were identiﬁed after electrophoresis on 12% SDS-PAGE. Std: internal standard. Panels B, C, D, and E show the values for the 75,
72, and 64 kDa molecular weight forms, and total MMP-2 levels, respectively, in the aortic extracts (n¼10–12 per group). Panel F shows total MMP-2 expression by Western
blotting in the thoracic aorta. Panel G shows densitometric intensity corresponding to each band normalized using β-actin (n¼6–8 per group). *Po0.05 for 2K1C+vehicle
group versus sham groups; **Po0.05 for 2K1C+Nebi group versus 2K1C+vehicle group.
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the lower MMP-2 and MMP-9 levels and activity.
MMPs are regulated at three levels: interaction with their
endogenous inhibitors (TIMPs), gene transcription, and posttran-
slational activation. MMP transcriptional levels and posttransla-
tional activation are regulated by oxidative stress. The lack of
differences in TIMP-1 levels among the groups studied suggests
that the increases in MMP activity reported here are not due to
alterations in the concentrations of this endogenous MMP inhi-
bitor. However, the decrease in oxidative stress reported here may
be responsible for the differences in MMP activity. ROS are potent
activators of transcription factors (such as NF-kB, AP-1, AP2/YB1/
p53, and NFAT) which bind the promoters of MMP-2 and MMP-9
genes to increase gene expression [42–44] in the cardiovascular
diseases. Posttranslational activation of MMPs by ROS has
also been described in several studies. Peroxynitrite activates
MMP-2 and MMP-9 via nonproteolytic mechanisms that include
S-glutathiolation and S-nitrosylation of the propeptide [14,15,43].
While both β1-blockers had no in vitro effects on rhMMP-2 activity,
the antioxidant properties of nebivolol [27,28,36] may have
blunted in vivo MMP-2 activation.
In addition, ROS are known to activate TGF-β [19,20], which
promotes collagen accumulation [38]. This peptide may also
stimulate ROS production by some cells types such as endothelial
cells, smooth muscle cells, and ﬁbroblasts, thus activating MMPs[38,45–47]. In the present study, the antioxidant effects exerted by
nebivolol, but not metoprolol, in hypertensive rats are probably a
major factor explaining lower TGF-β, MMP-2, and MMP-9 activity
and consequent less vascular remodeling, thus preventing against
proﬁbrotic mechanisms discussed above. This suggestion is sup-
ported by a previous work showing that nebivolol reduced MMP-2
and MMP-9 activity in endothelial cells following an oxidant
stimulus [48].
We found that 2K1C hypertension increased the expression of
p-ERK 1/2, a MAP kinase activated by angiotensin II that promotes
cell growth and contributes to development of vascular remodel-
ing [49]. While these results are in agreement with previous
ﬁndings [34], neither nebivolol nor metoprolol treatment affected
the expression of this proﬁbrotic factor in hypertensive animals.
Because ERK1/2 is directly activated in response to growth factors
such as angiotensin II, and by oxidative stress [49], it is possible
that the antioxidant effects of nebivolol were not sufﬁcient to
reduce p-ERK1/2 expression as this drug does not inhibit AT1
receptor [50].
Antioxidant treatments with vitamins (C and E) or SOD
mimetics (tempol (4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl)
have shown promising results in animal models of hypertension
and associated target organ damage. However a number of
preclinical and clinical studies examining the effects of these
classical antioxidants have shown disappointing results. There
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Fig. 5. In situ gelatinolytic activity and MMP-2 levels assessed by immunoﬂuorescence in the aortic media layer of 2K1C hypertension and effects of treatments. Panel A
shows representative photographs of gelatinolytic activity (400), MMP-2 levels, and their colocalization in the aortas. Panel B shows the mean gelatinolytic activity in
aortas in each study group assessed as bright green ﬂuorescence (n¼6 per group). Panel C shows the mean MMP-2 levels in the aortas in each study group assessed by bright
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Fig. 6. In situMMP-9 and TIMP-1 levels in the aortic media layer of 2K1C hypertension and effects of treatments, and in vitro effects of beta-blockers on human recombinant
MMP-2 activity. Panel A shows representative photographs of immunostaining of MMP-9 levels (400) by immunoﬂuorescence and representative photographs of
immunostaining of TIMP-1 levels (400) by immunohistochemistry. Panel B shows the mean MMP-9 levels assessed by bright red ﬂuorescence in the aortas in each study
group (n¼6 per group). Panel C shows the quantiﬁcation of brown staining of TIMP-1 (n¼6–8 per group). Panel D shows human recombinant MMP-2 activity measured
using a gelatinolytic activity kit, in the absence or presence of metoprolol (0, 1, 10, or 100 mmol L−1) or nebivolol (0, 1, 10, or 100 mmol L−1). Phenanthroline (Phen) was used as
a positive control for MMP-2 activity inhibition. Vehicle, DMSO 0.01%. Data are shown as mean7SEM of three experiments in duplicate. *Po0.05 for 2K1C+vehicle group
versus sham groups; **Po0.05 for 2K1C+Nebi group versus 2K1C+vehicle group. ***Po0.01 versus the respective zero concentration.
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Treatment with vitamin C and E may result in the formation of
vitamin radicals with paradoxical prooxidant properties, which
amplify oxidative damage. In addition, classic antioxidants sca-
venge already generated ROS and do not inhibit their production.
Many antioxidant compounds have been registered as NADPH
oxidase inhibitors, but they have not gone through clinical trials or
have not yet completed preclinical studies [51,52]. In this context,
drugs used to treat hypertension which exert antioxidant effects
may represent a promising alternative, such as nebivolol. This new
generation β-blocker directly activates nitric oxide synthase (NOS)
and preserves its activity by reducing the levels of the endogenous
NOS inhibitor AMDA. It also prevents NOS uncoupling, enhances
NO bioavailability, and inhibits NADPH oxidase activity [51,53].
Our results support the idea that nebivolol has antioxidant activity
and this property may prevent that activation of critical pathways
involved in hypertensive vascular remodeling (MMP-2, MMP-9,
TGF-β). These multiple beneﬁcial effects of nebivolol on the
cardiovascular system may suggest the use of nebivolol in a
broader range of cardiovascular disorders. However, clinical stu-
dies are necessary to validate this suggestion.
In conclusion, our study provides novel evidence that nebivolol,
but not metoprolol, attenuates prooxidant and proﬁbrotic mechan-
isms involving TGF-β and MMP-2, which promote vascular remo-
deling in hypertension. These beneﬁcial effects are probably not
directly dependent on the antihypertensive effects found with both
β1-blockers or β1 adrenoceptor-blocking properties.Acknowledgments
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